An investigation on behalf of NASDAQ:VRTX investors concerning potential securities laws violations by Vertex Pharmaceuticals Incorporated continues and NASDAQ:VRTX investors should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 07/25/2012 --The investigation for investors in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) concerning potential securities laws violations by Vertex Pharmaceuticals Incorporated in connection with certain financial statements continues.

Investors who purchased shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), you have certain options and you should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether the company, certain of its officers and directors, or others have possibly violated federal securities laws in connection with certain statements about Vertex Pharmaceuticals’ business, its prospects and its operations that were potentially materially false and misleading at the time they were made.

On May 7, 2012, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the Interim Data from the Phase 2 Combination Study of its VX-809 and KALYDECO™ (ivacaftor) showed significant improvements in Lung Function (FEV1) in people with cystic fibrosis who have two copies of the F508del mutation.

Then on May 29, 2012, before the market opened, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that it corrected and provided additional data from the recent interim analysis of Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) in people with cystic fibrosis who have two copies of the F508del mutation.

On Jun 28, 2012, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced final data from a Phase 2 study of VX-809 and KALYDECO™ (ivacaftor).

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) jumped from $37.41 per share on May 4, 2012 to $64.16 per share on May 8, 2012, but fell since then to $48.37 per share on July 24, 2012.

Those who purchased shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com